➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Medtronic
Merck
Mallinckrodt
Boehringer Ingelheim

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LYSTEDA

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Lysteda

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00113568 ↗ Safety Study of XP12B in Women With Menorrhagia Completed Ferring Pharmaceuticals Phase 3 2005-06-01 The purpose of this study is to evaluate the safety of XP12B in women with heavy menstrual bleeding associated with menorrhagia.
NCT00386308 ↗ Efficacy and Safety Study of XP12B in Women With Menorrhagia Completed Ferring Pharmaceuticals Phase 3 2006-10-01 The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
NCT00401193 ↗ Efficacy and Safety of XP12B in Women With Menorrhagia Completed Ferring Pharmaceuticals Phase 3 2006-11-01 The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
NCT01190150 ↗ Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding Completed Ferring Pharmaceuticals Phase 4 2010-08-01 This is a Phase 4, randomized, 2-way crossover, pharmacokinetic study of Lysteda (tranexamic acid) tablets administered as single doses of 0.65 g and 1.3 g in fasting adolescent female subjects ages 12-16 years with heavy menstrual bleeding.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lysteda

Condition Name

Condition Name for Lysteda
Intervention Trials
Heavy Menstrual Bleeding 5
Menorrhagia 5
Blood Loss, Surgical 3
Hip Replacement 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lysteda
Intervention Trials
Hemorrhage 11
Menorrhagia 8
Blood Loss, Surgical 3
Osteoarthritis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lysteda

Trials by Country

Trials by Country for Lysteda
Location Trials
United States 96
Australia 1
Brazil 1
Mexico 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lysteda
Location Trials
Ohio 4
California 4
Indiana 3
Virginia 3
Washington 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lysteda

Clinical Trial Phase

Clinical Trial Phase for Lysteda
Clinical Trial Phase Trials
Phase 4 5
Phase 3 6
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lysteda
Clinical Trial Phase Trials
Completed 5
Recruiting 4
Not yet recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lysteda

Sponsor Name

Sponsor Name for Lysteda
Sponsor Trials
Ferring Pharmaceuticals 4
Carnegie Mellon University 1
National Health and Medical Research Council, Australia 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lysteda
Sponsor Trials
Other 16
Industry 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Harvard Business School
Boehringer Ingelheim
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.